University opens market engagement on spatial transcriptomics platform
University seeks market insight on a high-resolution spatial transcriptomics platform for RNA and protein detection, highlighting demand for advanced tissue analysis.
University seeks market insight on a high-resolution spatial transcriptomics platform for RNA and protein detection, highlighting demand for advanced tissue analysis.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
Sapienza Università di Roma has set out plans to acquire a spatial transcriptomics platform that can map gene and protein expression directly in tissue. The move reflects a wider shift in public-sector genomics procurement towards high-resolution, in situ analysis rather than bulk sequencing alone.
On 13th April 2026, Sapienza Università di Roma published the Spatial Transcriptomic Platform Acquisition notice, signalling its intention to buy a new platform for advanced tissue-based gene expression studies.
The description is short but demanding. The university specifies the acquisition of a spatial transcriptomics platform:
Combining RNA and protein detection with high-resolution imaging and custom panels places the planned instrument squarely in the emerging spatial multiomics class, where sequencing-style readouts are anchored to precise locations within intact tissue.
Although the notice itself sits under an “Other” category, the Italian wording in the link refers to a “consultazione preliminare di mercato”, indicating a preliminary market consultation ahead of a negotiated procedure. The university is therefore signalling that this stage is about understanding available solutions and shaping a full tender, rather than awarding a contract immediately.
Beyond the core functions, the notice does not yet specify preferred sample types, throughput, automation or budget. Nor does it indicate whether installation, training, reagents or maintenance will be bundled into the eventual procurement. Those gaps leave space for suppliers to influence the final specification.
Sapienza’s move sits within a rapid build-out of spatial and single-cell capacity across European research centres.
In October 2025, FUNDACIÓN COMUNIDAD VALENCIANA CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE issued a contract notice for the Supply of Transcriptomics Equipment, covering molecular labelling and single-cell analysis alongside spatial expression tools. In November 2025, UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II followed with a tender for a Supply of Transcriptomics System able to assess entire transcriptomes and more than 570 target proteins across various sample types.
Also in November 2025, CNRS - Délégation Occitanie Ouest set out a detailed requirement in its Spatial Transcriptomics Equipment Supply notice. Beyond the instrument itself, the French laboratory required delivery, installation, commissioning, training and warranty, and insisted on compatibility with FFPE samples. That level of prescription shows spatial platforms moving from niche add-ons to standard infrastructure.
By March 2026, attention had turned explicitly to multiomics. Uppsala universitet launched a procurement for a Spatial Multiomics Platform Procurement to underpin spatial biology and cancer immunology, including high-resolution protein and RNA detection as well as installation, training and maintenance. On 18th March 2026, FUNDACIÓ INSTITUT RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS published a contract for Spatial Transcriptomics Platform Services, again bundling supply with commissioning, training and maintenance.
Imaging-focused tenders reinforce this convergence between sequencing and microscopy. Umeå universitet’s March 2026 call for a High-performance imaging system centres on spatial proteomic profiling through multiplex immunohistochemistry on whole tissue sections and microarrays. Masarykova univerzita has similarly gone to market for a Multiplex Imaging System capable of simultaneous multicolour fluorescence detection of multiple protein markers while preserving tissue morphology.
Service-led models are emerging alongside capital purchases. Maynooth University’s March 2026 competition for Spatial Transcriptomics Services seeks external spatial and single-cell transcriptomic analysis of human tissues to identify disease drivers and drug-resistance targets, opting to procure processing and analysis capacity rather than instruments.
Spatial platforms sit on top of an expanding base of sequencing and gene-expression infrastructure, and recent procurements show how buyers are building that stack.
In February 2026, Università della Calabria advertised a Single-Cell Sequencing System for genomic and transcriptomic data analysis. Days later, Fakultní nemocnice Motol a Homolka launched a tender for Whole-Transcriptome Sequencing Systems to equip a scientific and diagnostic oncology centre. Where those projects concentrate on sequencing throughput, Sapienza’s platform aims to add spatial context.
Service contracts are complementing hardware investments. In December 2025, Fundación Instituto de Investigación Sanitaria Illes Balears sought Genomic Sequencing Services covering high-resolution whole-genome and RNA sequencing for a range of biomedical projects. In January 2026, AULSS N 1 DOLOMITI launched a procedure for the Supply of Analytical Systems and reagents for molecular biology investigations, focusing on sexually transmitted diseases, gastrointestinal infections and testing for transplanted and immunocompromised patients using real-time PCR.
Reagents and consumables are becoming long-term strategic items. ASST DEI SETTE LAGHI’s December 2025 Procurement of NGS Reagents covers library preparation and sequencing cartridges for Illumina platforms at a specialist medical genetics laboratory. On 28th January 2026, Grande Ospedale Metropolitano di Reggio Calabria issued its own tender for the Supply of NGS Reagents to support high-throughput clinical genetics.
Adjacent technologies still matter. IRCCS Policlinico San Martino’s December 2025 competition for a Supply of FISH Consumables keeps fluorescence in situ hybridisation at the forefront of molecular cytogenetics. Meanwhile, Warszawski Uniwersytet Medyczny’s January 2026 tender for a Real-Time Gene Expression Detection System couples sustainability principles with a clear statement that equivalent technical solutions are welcome.
Outside Europe, US federal buyers are also reshaping their RNA-sequencing estates. In April 2026, the Department of Health and Human Services announced its intent to sole-source 10X Genomics reagents through a Sole Source for RNA Sequencing Reagents notice tied to Alzheimer’s research. A day later, the Department of Veterans Affairs prepared a sole-source contract with New York Genome Center for Research Study Services for RNA Sequencing in a study of blast-related traumatic brain injury. These cases underline how platform continuity and data comparability can sometimes justify non-competitive routes.
Sapienza’s preliminary stance mirrors a growing reliance on market consultations and exploratory notices when procuring sophisticated genomic and imaging systems.
In November 2025, ASL2 SISTEMA SANITARIO REGIONE LIGURIA opened a Market Consultation for Oncological Diagnostics to shape an open procedure for a combined system to study clinically relevant genetic variants, complete with assistance services and consumables. On 26th February 2026, Azienda Regionale della Salute (ARES) launched a Market Consultation for Diagnostic Systems covering NGS sequencing platforms, automated library preparation and data-analysis systems for ASL of Cagliari.
Istituto di Nanotecnologia del Consiglio Nazionale delle Ricerche (CNR NANOTEC) adopted the same tactic in January 2026 with a Market Investigation for Microscopy Platform, exploring options for a histological and materialographic preparation system to support multimodal microscopy under a national investment plan.
Perhaps the closest parallel to Sapienza’s ambitions is the April 2026 prior information notice from Sieć Badawcza Łukasiewicz - PORT Polski Ośrodek Rozwoju Technologii for Spatial Transcriptomics System Delivery. That project seeks a subcellular-resolution spatial transcriptomics platform with essential equipment, a starter reagent kit, training for staff and warranty coverage, illustrating the breadth of support packages now expected around high-end systems.
Across these notices, a common pattern emerges: buyers want platforms that integrate RNA and protein readouts, deliver high optical resolution and come with strong training, maintenance and reagent support. Sapienza’s brief specification, emphasising in situ tissue analysis, RNA and protein detection and customisable panels, tracks that pattern closely.
If the university follows the trajectory seen in other spatial and multiomic procurements, subsequent documents may clarify expectations around sample compatibility, target resolution down to cellular or subcellular level, multiplexing capacity and data-analysis workflows. Suppliers active in this market will watch for whether the eventual procedure bundles consumables and services, as in the Łukasiewicz and Josep Carreras projects, or focuses on capital equipment alone.
For researchers, the planned acquisition signals continued investment in technologies that keep spatial context intact while interrogating gene and protein expression. For industry, it offers another chance to influence how next-generation platforms are specified and deployed in major academic laboratories.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.